Biomarker AnaLysis for Diabetes Research



* e-mail is optional



BALDR is an automated pipeline for biomarker comparison and prioritization in the context of diabetes. BALDR includes protein, gene and disease data from major public repositories, text-mining data and human and mouse experimental data from the IMI2 RHAPSODY consortium. These data are provided as easy-to-read figures and tables enabling direct comparison of up to 20 biomarker candidates for diabetes.

BALDR uses data from five major public databases: UniProt, PHAROS, Open Targets, DrugBank, and the Human Protein Atlas (HPA) that contain functional, interactional, and disease-relevant information for the human proteome. In BALDR, we utilize these data to inform on the relevance of proteins as novel, biologically relevant biomarkers for diabetes.

BALDR include observational and experimental data from the Risk Assessment and ProgreSsiOn of Diabetes (RHAPSODY) consortium, financed by EU Innovative Medicines Initiative-2. Within RHAPSODY, a large quantity of omics data has been generated, based on a federation of clinical cohorts that include patients in varying stages of diabetes, as well as human tissue analysis and mouse experiments conducted within the consortium.

Lastly, BALDR contains results from text mining of 15 million full text articles, protein-protein interaction data from STRING and gene enrichment information from WebGestaltR.


BALDR: A Web-based platform for informed comparison and prioritization of biomarker candidates for type 2 diabetes mellitus.
Lundgaard AT, Burdet F, Siggaard T, Westergaard D, Vagiaki D, Cantwell L, et al. (2023)
PLoS Comput Biol 19(8): e1011403.


Novo Nordisk Foundation (Grant agreement NNF14CC0001)

RHAPSODY project: IMI (Grant agreement 115881), EU Horizon 2020, EFPIA & SERI


Copyright © 2022 BALDR, Brunak group, Novo Nordisk Foundation Center for Protein Research, SUND, University of Copenhagen.